Modulation of non-N-methyl-D-aspartate receptors in cultured cerebellar granule cells.
Kainic acid (KA), quisqualic acid (QUIS), and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) stimulated D-[3H]aspartate release from cultured cerebellar granule cells in a concentration-dependent way. The EC50 values were 50 microM for KA (Gallo et al., 1987) and 20 microM for both QUIS and AMPA, but the efficacy of QUIS appeared to be greater than that of AMPA. The release of D-[3H]aspartate induced by KA, QUIS, and AMPA was blocked, in a dose-dependent way, by the new glutamate receptor antagonist 6-cyano-2,3-dihydroxy-7-nitroquinoxaline (CNQX); IC50 values were 0.7 microM in the case of AMPA (50 microM) and 1 microM in the case of KA (50 microM). AMPA (50-300 microM) inhibited the effect of 50 microM KA on D-[3H]aspartate release. At 300 microM AMPA, the effect of KA plus AMPA was not antagonized by the KA receptor antagonist kynurenic acid (KYN). In contrast, when KA was used at an ineffective concentration (10 microM), the addition of AMPA at concentrations below the EC50 value (10-20 microM) resulted in a synergistic effect on D-[3H]aspartate release. In this case, the evoked release of D-[3H]aspartate was sensitive to KYN. KA stimulated the formation of cyclic GMP, whereas QUIS, AMPA, and glutamate were ineffective. The accumulation of cyclic GMP elicited by KA (100 microM) was prevented not only by the antagonists CNQX (IC50 = 1.5 microM) and KYN (IC50 = 200 microM), but also by the agonists AMPA (IC50 = 50 microM) QUIS (IC50 = 3.5 microM), and glutamate (IC50 = 100 microM). We conclude that AMPA, like QUIS, may act as a partial agonist at KA receptors. Moreover, CNQX effectively antagonizes non-N-methyl-D-aspartate receptor-mediated responses in cultured cerebellar granule cells.
Gallo
V
V
Neurobiology Section, Istituto Superiore di Sanità, Rome, Italy.
Giovannini
C
C
Levi
G
G
D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism; D002478:Cells, Cultured; D002531:Cerebellum / Q000166:cytology / Q000378:metabolism*; D006152:Cyclic GMP / Q000096:biosynthesis; D006098:Granulocytes / Q000378:metabolism*; D007051:Ibotenic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D007608:Kainic Acid / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate; D017981:Receptors, Neurotransmitter / Q000378:metabolism*; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
D011810:Quinoxalines; D016194:Receptors, N-Methyl-D-Aspartate; D017981:Receptors, Neurotransmitter; D007051:Ibotenic Acid; D001224:Aspartic Acid; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; D006152:Cyclic GMP; D007608:Kainic Acid